BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. AnGes submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2007. In addition, Naglazyme obtained orphan designation in June 2007 from the MHLW in Japan.
Stephen Aselage, senior vice president of global commercial development at BioMarin, said: “We are proud to work with AnGes in bringing the first drug treatment option to MPS VI patients in Japan.”